Alzheimer’s: a small trial explores virtual reality to ease agitation

Group therapy compared with usual care

The researchers evaluated a group-based multisensory reminiscence therapy using virtual reality. The intervention aims to draw on autobiographical memories in an immersive environment. The study therefore assessed a supported therapeutic intervention, not independent use of a headset.

The 60 participants were randomly assigned to two groups of 30 people. The experimental group attended two 40-minute sessions per week for eight weeks. The control group received usual care. The assessors were unaware of the participants’ group assignments.

Before and after the intervention, several questionnaires and tests measured agitation, cognitive abilities, depressive symptoms, and certain aspects of social functioning and mental health. The researchers also assessed the accuracy of autobiographical memories, acceptance of the intervention, and adverse effects.

Reported benefits, but figures that are difficult to interpret

The authors conclude that agitation, cognition, and mood improved, along with certain aspects of quality of life. They also report improved accuracy of autobiographical memories.

However, the abstract describes MMSE cognitive scores as lower, whereas the values presented and the conclusion suggest an improvement. The order of the reported values also makes it impossible to clearly identify which groups or time points are being compared for each outcome. Reporting these figures as definite between-group differences would create misleading precision.

The signal is therefore interesting, but the size of the benefit still needs to be checked against the full text. The abstract also does not establish whether the observed changes translate into lasting improvements in everyday life.

The specific contribution of virtual reality remains to be isolated

The comparator is an important limitation: usual care does not allow the effects of virtual reality to be distinguished from those of group interaction, the attention received, or reminiscence work. This trial therefore does not demonstrate that a headset offers more than a comparable intervention without virtual reality.

The questionnaires indicate good acceptance and adverse effects described as minor, including eye strain. This provides information about tolerability during this trial, without establishing general or long-term safety.

With a small sample and an assessment reported at eight weeks, these results mainly offer a promising avenue that needs confirmation. Funding and conflicts of interest are not specified in the supplied excerpt and could not be verified.

What we can take away

This trial suggests potential value in group reminiscence combined with virtual reality for Alzheimer’s. It is not enough to establish the specific effectiveness of the technology or whether the benefits last.